Oxybutynin Chloride Syrup Rx
Generic Name and Formulations:
Oxybutynin chloride 5mg/5mL.
Various generic manufacturers
Indications for Oxybutynin Chloride Syrup:
Symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (eg, urinary urgency, frequency, leakage, urge incontinence, dysuria).
5mg 2–3 times a day; max 20mg/day.
<5yrs: not recommended. ≥5yrs: 5mg twice daily; max 15mg/day.
Uncontrolled glaucoma. GI obstruction. Paralytic ileus. Intestinal atony in elderly or debilitated. Severe colitis. Myasthenia gravis. Megacolon. Toxic megacolon in ulcerative colitis. Obstructive uropathies. Unstable cardiovascular status in acute hemorrhage.
Activities requiring mental alertness. Diarrhea. Hepatic or renal disease. Autonomic neuropathy. Hyperthyroidism. Cardiovascular disease. Hiatal hernia. GI or GU obstruction. Ulcerative colitis. Exposure to extreme heat. Elderly. Pregnancy (Cat.B). Nursing mothers.
Potentiates drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors. Decreases GI motility, possibly affecting absorption of other drugs.
Dry mouth, constipation, somnolence, headache, diarrhea, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.
Formerly known under the brand name Ditropan.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies